Pliant Therapeutics Inc
PLRX
Company Profile
Business description
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.
Contact
331 Oyster Point Boulevard
South San FranciscoCA94080
USAT: +1 650 481-6770
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
49
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,836.70 | 71.20 | 0.81% |
| CAC 40 | 8,242.59 | 80.76 | 0.99% |
| DAX 40 | 24,300.00 | 104.69 | 0.43% |
| Dow JONES (US) | 50,276.32 | 357.54 | 0.72% |
| FTSE 100 | 10,357.93 | 103.12 | 1.01% |
| HKSE | 24,249.29 | 158.67 | -0.65% |
| NASDAQ | 25,446.94 | 277.44 | 1.10% |
| Nikkei 225 | 64,217.27 | 38.00 | 0.06% |
| NZX 50 Index | 13,202.16 | 51.49 | -0.39% |
| S&P 500 | 7,321.94 | 54.95 | 0.76% |
| S&P/ASX 200 | 8,633.20 | 69.70 | 0.81% |
| SSE Composite Index | 3,987.01 | 6.21 | -0.16% |